Shares of Acelyrin, Inc. (NASDAQ:SLRN – Get Free Report) have received an average rating of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $12.00.
SLRN has been the topic of several recent analyst reports. Piper Sandler cut their target price on Acelyrin from $68.00 to $20.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 14th. HC Wainwright cut Acelyrin from a “buy” rating to a “neutral” rating and cut their target price for the stock from $18.00 to $6.00 in a research note on Wednesday, August 14th. Finally, Wells Fargo & Company raised Acelyrin from an “equal weight” rating to an “overweight” rating and set a $13.00 target price on the stock in a research note on Monday, July 8th.
Read Our Latest Analysis on Acelyrin
Institutional Trading of Acelyrin
Acelyrin Trading Up 3.8 %
Shares of NASDAQ:SLRN opened at $4.13 on Wednesday. The stock’s 50-day moving average price is $5.10 and its 200-day moving average price is $5.80. Acelyrin has a 12-month low of $3.36 and a 12-month high of $29.88. The stock has a market capitalization of $412.22 million, a P/E ratio of -1.74 and a beta of 2.35.
Acelyrin (NASDAQ:SLRN – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). During the same quarter in the previous year, the company earned ($0.56) earnings per share. As a group, research analysts predict that Acelyrin will post -2.95 EPS for the current year.
About Acelyrin
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Further Reading
- Five stocks we like better than Acelyrin
- How to Invest in the FAANG Stocks
- This Small Cap Wealth Management Stock Could Provide Big Returns
- What is the Shanghai Stock Exchange Composite Index?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- How to Evaluate a Stock Before Buying
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Acelyrin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acelyrin and related companies with MarketBeat.com's FREE daily email newsletter.